Iovance Biotherapeutics (IOVA) Short Interest Ratio & Short Volume $1.88 +0.03 (+1.35%) As of 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Iovance Biotherapeutics Short Interest DataIovance Biotherapeutics (IOVA) has a short interest of 86.36 million shares, representing 31.81% of the float (the number of shares available for trading by the public). This marks a 12.13% increase in short interest from the previous month. The short interest ratio (days to cover) is 6.7, indicating that it would take 6.7 days of the average trading volume of 8.94 million shares to cover all short positions.Current Short Interest86,360,000 sharesPrevious Short Interest77,020,000 sharesChange Vs. Previous Month+12.13%Dollar Volume Sold Short$151.30 millionShort Interest Ratio6.7 Days to CoverLast Record DateMay 31, 2025Outstanding Shares333,930,000 sharesFloat Size271,490,000 sharesShort Percent of Float31.81%Today's Trading Volume5,023,532 sharesAverage Trading Volume8,938,922 sharesToday's Volume Vs. Average56% Short Selling Iovance Biotherapeutics? Sign up to receive the latest short interest report for Iovance Biotherapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartIOVA Short Interest Over TimeIOVA Days to Cover Over TimeIOVA Percentage of Float Shorted Over Time Iovance Biotherapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/31/202586,360,000 shares $151.30 million +12.1%31.8%6.7 $1.75 5/15/202577,020,000 shares $135.56 million +3.3%28.4%5.8 $1.76 4/30/202574,570,000 shares $267.71 million +4.5%27.6%6.3 $3.59 4/15/202571,370,000 shares $230.53 million -5.1%26.9%7.4 $3.23 3/31/202575,190,000 shares $250.38 million +11.7%28.3%7.6 $3.33 3/15/202567,300,000 shares $241.61 million +12.9%25.3%7.2 $3.59 2/28/202559,590,000 shares $252.66 million -6.3%22.4%6.7 $4.24 2/15/202563,600,000 shares $354.25 million -0.5%25.7%8.6 $5.57 1/31/202563,910,000 shares $373.87 million +3.1%26.0%7.8 $5.85 1/15/202561,980,000 shares $366.30 million +1.1%25.1%8.1 $5.91 Get the Latest News and Ratings for IOVA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/31/202461,310,000 shares $453.69 million +3.3%24.8%8.9 $7.40 12/15/202459,330,000 shares $464.55 million +4.2%24.0%9.6 $7.83 11/30/202456,920,000 shares $530.49 million +5.4%23.1%9.3 $9.32 11/15/202453,990,000 shares $441.64 million -9.6%21.9%8.6 $8.18 10/31/202459,730,000 shares $623.58 million -1.0%24.1%10.2 $10.44 10/15/202460,340,000 shares $578.66 million +0.7%24.4%10.1 $9.59 9/30/202459,950,000 shares $562.93 million -0.6%24.3%9.7 $9.39 9/15/202460,290,000 shares $623.40 million +4.5%24.4%8.9 $10.34 8/31/202457,690,000 shares $672.67 million -2.8%23.3%8 $11.66 8/15/202459,330,000 shares $633.05 million -3.3%24.5%8 $10.67 7/31/202461,320,000 shares $535.32 million +4.0%27.4%8.3 $8.73 7/15/202458,940,000 shares $511.60 million +4.5%26.4%9 $8.68 6/30/202456,420,000 shares $452.49 million +3.3%25.2%9 $8.02 6/15/202454,630,000 shares $445.78 million +9.4%24.4%9.3 $8.16 5/31/202449,960,000 shares $443.64 million -2.4%22.3%8.5 $8.88 5/15/202451,210,000 shares $546.92 million +2.3%22.9%7.8 $10.68 4/30/202450,060,000 shares $589.71 million +2.2%22.6%5.7 $11.78 4/15/202448,980,000 shares $582.37 million +5.6%22.2%5.5 $11.89 3/31/202446,380,000 shares $687.35 million -2.2%21.1%4.9 $14.82 3/15/202447,430,000 shares $659.75 million +1.5%21.6%4.6 $13.91 2/29/202446,710,000 shares $743.16 million +8.7%21.2%4.5 $15.91 2/15/202442,980,000 shares $424.21 million +2.4%20.1%4.4 $9.87 1/31/202441,970,000 shares $324.43 million -3.0%21.0%5.6 $7.73 1/15/202443,270,000 shares $389.86 million +18.8%21.7%5.7 $9.01 12/31/202336,410,000 shares $296.01 million +3.2%18.2%4.8 $8.13 12/15/202335,280,000 shares $274.48 million +2.0%17.7%5.1 $7.78 11/30/202334,590,000 shares $209.96 million -2.8%17.5%4.7 $6.07 11/15/202335,590,000 shares $169.05 million -8.4%18.0%5.2 $4.75 10/31/202338,860,000 shares $148.45 million +0.3%19.4%6 $3.82 10/15/202338,740,000 shares $140.63 million +5.4%19.4%6.4 $3.63A grave, grave error. (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. 9/30/202336,770,000 shares $167.30 million +20.5%18.4%6 $4.55 9/15/202330,510,000 shares $160.79 million +1.5%15.3%4.9 $5.27 8/31/202330,070,000 shares $181.62 million +9.2%14.7%6.2 $6.04 8/15/202327,530,000 shares $206.75 million -0.1%13.5%4.6 $7.51 7/31/202327,550,000 shares $200.01 million +6.1%13.6%4.6 $7.26 7/15/202325,960,000 shares $201.45 million -10.1%13.1%4.4 $7.76 6/30/202328,890,000 shares $203.39 million +12.8%14.6%5.1 $7.04 6/15/202325,620,000 shares $221.36 million +18.3%14.1%4.8 $8.64 5/31/202321,650,000 shares $189.22 million -7.4%11.9%4.4 $8.74 5/15/202323,380,000 shares $183.30 million No Change12.9%5.9 $7.84 10/31/202217,260,000 shares $161.21 million -5.0%12.2%8 $9.34 10/15/202218,170,000 shares $160.80 million -2.6%12.7%8.2 $8.85 9/30/202218,660,000 shares $178.76 million -4.5%13.0%8 $9.58 9/15/202219,540,000 shares $231.94 million -0.6%13.7%6.5 $11.87 8/31/202219,650,000 shares $210.65 million -5.4%13.7%5.6 $10.72 8/15/202220,760,000 shares $266.77 million +6.9%14.5%4.1 $12.85 7/31/202219,420,000 shares $226.24 million -2.6%14.0%3.8 $11.65 7/15/202219,940,000 shares $255.23 million -7.5%14.3%4.1 $12.80 6/30/202221,550,000 shares $237.91 million +30.1%15.5%4.4 $11.04 6/15/202216,560,000 shares $135.79 million -4.7%11.9%3.5 $8.20 5/31/202217,370,000 shares $117.25 million +1.0%12.5%4.6 $6.75 5/15/202217,200,000 shares $242.00 million +8.8%12.4%8.2 $14.07 4/30/202215,810,000 shares $239.52 million +3.7%11.4%7.7 $15.15 4/15/202215,250,000 shares $268.71 million +9.9%11.0%7.3 $17.62 3/31/202213,880,000 shares $231.10 million +1.5%N/A6.3 $16.65 3/15/202213,680,000 shares $171.14 million -0.3%9.9%6.7 $12.51 2/28/202213,720,000 shares $214.99 million +9.4%10.1%7 $15.67 2/15/202212,540,000 shares $223.96 million +11.6%9.2%6.3 $17.86 1/31/202211,240,000 shares $187.15 million -6.5%8.3%5.3 $16.65 1/15/202212,020,000 shares $186.19 million -3.6%N/A5.7 $15.49 12/31/202112,470,000 shares $238.05 million -6.9%9.1%6.7 $19.09 12/15/202113,390,000 shares $247.85 million -14.3%9.8%7.9 $18.51 11/30/202115,620,000 shares $292.41 million -1.1%11.5%9.5 $18.72 11/15/202115,800,000 shares $309.52 million +3.7%11.6%10.2 $19.59 10/29/202115,230,000 shares $370.24 million +0.3%11.1%11.2 $24.31 10/15/202115,190,000 shares $404.21 million +3.8%11.2%11.2 $26.61 9/30/202114,640,000 shares $361.02 million -5.5%10.8%10 $24.66 9/15/202115,490,000 shares $372.22 million -6.7%11.5%9.4 $24.03 8/31/202116,600,000 shares $399.56 million -2.0%12.3%9 $24.07 8/13/202116,940,000 shares $368.78 million -1.7%12.5%7.5 $21.77 7/30/202117,240,000 shares $383.93 million -3.5%12.7%4.8 $22.27 7/15/202117,860,000 shares $402.39 million +0.7%12.7%4.9 $22.53 6/30/202117,730,000 shares $461.33 million -14.4%12.6%4.8 $26.02 6/15/202120,720,000 shares $490.65 million -7.2%14.7%5.5 $23.68 5/28/202122,330,000 shares $414.67 million +11.0%15.9%6.1 $18.57 5/14/202120,120,000 shares $503.20 million +1.9%N/A5.8 $25.01 4/30/202119,750,000 shares $618.97 million -1.5%N/A9.7 $31.34 4/15/202120,040,000 shares $601.00 million -6.0%N/A10.8 $29.99 3/31/202121,320,000 shares $631.92 million +43.3%N/A12 $29.64 3/15/202114,880,000 shares $516.19 million +6.4%N/A10.1 $34.69A grave, grave error. (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. 2/26/202113,980,000 shares $510.41 million +9.4%N/A10 $36.51 2/12/202112,780,000 shares $610.25 million -9.0%N/A10.3 $47.75 1/29/202114,050,000 shares $613.28 million -8.4%N/A11.7 $43.65 1/15/202115,340,000 shares $798.14 million -1.2%N/A12.8 $52.03 12/31/202015,530,000 shares $757.24 million -5.4%N/A12 $48.76 12/15/202016,410,000 shares $824.77 million -2.2%N/A10.9 $50.26 11/30/202016,780,000 shares $660.80 million +1.3%N/A12.1 $39.38 11/15/202016,570,000 shares $625.02 million -0.1%N/A11.7 $37.72 10/30/202016,590,000 shares $595.25 million +9.4%N/A11.9 $35.88 10/15/202015,160,000 shares $524.54 million +17.3%N/A10.9 $34.60 9/30/202012,920,000 shares $425.33 million -7.0%N/A10.2 $32.92 9/15/202013,890,000 shares $496.15 million -4.6%N/A10.4 $35.72 8/31/202014,560,000 shares $485.28 million +1.0%N/A10 $33.33 8/14/202014,410,000 shares $400.45 million +3.2%N/A8 $27.79 7/31/202013,960,000 shares $405.82 million -2.4%11.9%7.3 $29.07 7/15/202014,300,000 shares $431.00 million -2.3%12.2%6.9 $30.14 6/30/202014,640,000 shares $398.35 million -1.2%12.5%6.7 $27.21 IOVA Short Interest - Frequently Asked Questions What is Iovance Biotherapeutics' current short interest? Short interest is the volume of Iovance Biotherapeutics shares that have been sold short but have not yet been closed out or covered. As of May 31st, investors have sold 86,360,000 shares of IOVA short. 31.81% of Iovance Biotherapeutics' shares are currently sold short. Learn More on Iovance Biotherapeutics' current short interest. What is a good short interest ratio for Iovance Biotherapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IOVA shares currently have a short interest ratio of 7.0. Learn More on Iovance Biotherapeutics's short interest ratio. Which institutional investors are shorting Iovance Biotherapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Iovance Biotherapeutics: Jane Street Group LLC, Caption Management LLC, Walleye Trading LLC, Walleye Capital LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Iovance Biotherapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 31.81% of Iovance Biotherapeutics' floating shares are currently sold short. Is Iovance Biotherapeutics' short interest increasing or decreasing? Iovance Biotherapeutics saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 86,360,000 shares, an increase of 12.1% from the previous total of 77,020,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Iovance Biotherapeutics' float size? Iovance Biotherapeutics currently has issued a total of 333,930,000 shares. Some of Iovance Biotherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Iovance Biotherapeutics currently has a public float of 271,490,000 shares. How does Iovance Biotherapeutics' short interest compare to its competitors? 31.81% of Iovance Biotherapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Iovance Biotherapeutics: ImmunityBio, Inc. (62.35%), MoonLake Immunotherapeutics (11.92%), Organon & Co. (6.75%), Immunovant, Inc. (31.62%), Amneal Pharmaceuticals, Inc. (2.93%), Mirum Pharmaceuticals, Inc. (16.37%), Xenon Pharmaceuticals Inc. (4.68%), Apellis Pharmaceuticals, Inc. (21.59%), NewAmsterdam Pharma (10.54%), Bausch Health Companies Inc. (2.96%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($64.96 billion), Invesco QQQ ($27.88 billion), iShares Russell 2000 ETF ($19.94 billion), iShares 20+ Year Treasury Bond ETF ($9.69 billion), MicroStrategy Incorporated ($8.58 billion), SPDR S&P Biotech ETF ($5.72 billion), Invesco S&P 500 Equal Weight ETF ($5.45 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.70 billion), Charter Communications, Inc. ($4.54 billion), and Industrial Select Sector SPDR Fund ($4.49 billion). View all of the most shorted stocks. What does it mean to sell short Iovance Biotherapeutics stock? Short selling IOVA is an investing strategy that aims to generate trading profit from Iovance Biotherapeutics as its price is falling. IOVA shares are trading down $0.13 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Iovance Biotherapeutics? A short squeeze for Iovance Biotherapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IOVA, which in turn drives the price of the stock up even further. How often is Iovance Biotherapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IOVA, twice per month. The most recent reporting period available is May, 31 2025. More Short Interest Resources from MarketBeat Related Companies IBRX Short Interest MLTX Short Interest OGN Short Interest IMVT Short Interest AMRX Short Interest MIRM Short Interest XENE Short Interest APLS Short Interest NAMS Short Interest BHC Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:IOVA) was last updated on 6/24/2025 by MarketBeat.com Staff From Our PartnersWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… and it's all thanks to President Trump. His administr...InvestorPlace | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredIs Tesla a buy right now?Wall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin...Chaikin Analytics | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredYour portfolio has a dangerous blind spot (fix it now)The next overnight crash could happen any day. Will you be protected or exposed? Register now to learn how som...Ninjacators | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredA grave, grave error.It seems like the world is on fire. Trump’s tariffs are crippling economies worldwide. Canada’s been cri...Porter & Company | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
